案例报告:在降脂药物下揭露非特异性不良影响的实践方法
Thomas Büttner1, Gunther Hartmann1, Martin Coenen1
1Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
Frontiers in cardiovascular medicine
|June 11, 2025
概括
诺塞博效应显著影响药物坚持. 一个盲目的,安慰剂控制的测试有助于区分nocebo反应与真正的药物不耐受性,使持续的他类药物治疗.
科学领域:
- 临床药理学 临床药理学
- 精神病体医学是一种精神病体医学.
背景情况:
- 由负面期望驱动的nocebo效应导致显著的药物不坚持,特别是在像他类药物这样的降脂疗法中.
- 高达50%的类他类药物相关不良反应可能来自于nocebo反应,导致过早停止治疗和增加心血管风险.
研究的目的:
- 提交一份病例报告,详细说明使用盲目,安慰剂控制的挑测试来区分nocebo效应和真正的药物不耐受性,患者经历了降脂药物的不良症状.
- 展示一个务实的,逐步的方法,在常规的临床实践中实施这种测试.
主要方法:
- 一名65岁的女性患有高胆固醇和心血管风险因素,经历了与降脂药物重复出现的腹痛,接受了为期六周的单盲,安慰剂控制的交叉挑测试.
- 该测试涉及在中性容器中给予安慰剂和阿托瓦斯塔丁,患者在数值评分尺度上对症状严重程度进行评分.
主要成果:
- 患者在安慰剂和阿托瓦斯塔丁阶段报告了类似的间歇性症状,疼痛评级没有显著差异 (安慰剂:2.75,阿托瓦斯塔丁:3.26).
- 这种指定的症状不是药理上诱导的,允许继续阿托瓦斯塔丁治疗.
- 随后继续服用阿托瓦斯塔丁导致症状减轻,增强了解决nocebo效应的治疗价值.
结论:
- 在临床实践中,盲目,安慰剂控制的挑测试是区分真正的药物不耐受性和无效果效应的有效方法.
- 这种方法可以通过识别和管理nocebo驱动的症状,继续必要的治疗,如他类药物.
- 病例报告提供了一个详细的,务实的协议,用于在日常护理中实施这种诊断和治疗策略.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
584
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
584
01:19Pharmacovigilance
786
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
786
01:23Assessment of the Cardiovascular System I: Subjective Data
282
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
282
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
51
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
51
01:25Dose-Response Relationship: Selectivity and Specificity
6.5K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.5K
01:28Structure-Activity Relationships and Drug Design
676
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
676